

To:

Director of Pharmaceutical Care, Royal Hospital
Director of Pharmaceutical Care, Khoula Hospital
Pharmacist Incharge, Al Nahda Hospital
Director General of Health Services in all Governorates
Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Health Institutions)
Director of Pharmaceutical Care, DGMS
Pharmacist Incharge, Al Massarah Hospital
The Head of Medical Services in University Medical City
The Head of Medical Services in Medical City for Military and Security Services
Director of Pharmacy of Qaboos Comprehensive Cancer Care & Research Center
Pharmacist Incharge, The Sultan's Special Force
Pharmacist Incharge, Internal Security Services
Pharmacist Incharge, Petroleum Development of Oman
Pharmacist Incharge, LNG Oman
All Private Pharmacies & Drug Stores

After Compliments,

Kindly find attached our Circular No. 104 dated 21/10/2026 Regarding Alert to Health Care Professionals About falsified product marketed as (Retatrutide).

Copy to:

- Director of Pharmacovigilance Department, DSC
- Director of Medicine Registration Department, DSC
- Director of Regulatory Compliance Department, DSC
- Director of Central Quality Control Lab., DSC
- Director of Medical Device Department, DSC
- Section Head of Medicine Safety Evaluation
- Section Head of Quality Problems and Medication Errors.
- Section Head of Pharmacovigilance
- Section Head of Clinical Trials

Circular No. 104/2026

10 -05-1448 H
21 -10-2026

Subject: falsified product marketed as (Retatrutide)

The Drug Safety Center (DSC) would like to share a safety alert issued by the Australian Therapeutic Goods Administration (TGA) regarding products marketed as “Retatrutide” for weight loss. The TGA highlighted the following:

- **Serious health risk:** Products marketed as Retatrutide for weight loss may pose a serious risk to health and should not be used.
- **Reported serious adverse event:** The TGA received a report of uncontrollable vomiting following use of a product sold as Retatrutide. The vomiting resulted in a torn oesophagus and required hospital treatment.
- **Laboratory findings:** During its investigation, the TGA obtained a sample of the product in its original unmarked vial. Laboratory testing found that:
 - The tested product contained undeclared semaglutide and no retatrutide.
 - The amount of semaglutide detected was approximately eight times higher than the level found in semaglutide products assessed by the TGA and included in the Australian Register of Therapeutic Goods.
- **Regulatory status:** At the time of the alert, Retatrutide was undergoing clinical trials in humans and had not been approved by the TGA or any comparable international regulator.
- **Warning against use outside clinical trials:** Any product supplied as Retatrutide outside clinical trials could be counterfeit and should not be used outside a clinical trial setting.
- **Risks associated with unapproved injectable peptides:** These products may contain unknown ingredients, incorrect amounts of active substances, or contaminants. Uncertain sterility and unsafe injection practices may also increase the risk of infection, anaphylaxis and other serious adverse reactions.

Advice for Healthcare Professionals:

- Do not prescribe, dispense or administer products marketed as Retatrutide outside an authorized clinical trial.
- If a suspected falsified product is identified, stop its use, segregate any remaining stock and notify DSC. Retain the product, packaging, photographs and supplier details for investigation.
- Ask patients about weight-loss injections obtained online or from unverified sources. Assess patients who have used a suspected product and manage any adverse effects according to their clinical condition.
- All medical products must be obtained from authorized/licensed suppliers.

Advice for Patients:

Do not use products sold as Retatrutide outside a clinical trial. If you have used a suspected product, contact a healthcare professional. Seek urgent medical attention for severe or persistent vomiting, severe chest or abdominal pain, breathing difficulties or signs of a serious allergic reaction. Keep the product and packaging for investigation.

Call to report:

Healthcare professionals, patients and caregivers are requested to report suspected falsified products and associated adverse events to the Pharmacovigilance Department at the Drug Safety Center. Include available product details, source of supply, exposure information and clinical outcome.



Ph. Ibrahim Nasser Al Rashdi
Director General

